Cero will use Invivoscribe's multiparametric flow cytometry assay to detect minimal residual disease in patients and evaluate the therapy's efficacy.

Ashwin Kishtagari, MD, of Vanderbilt University Medical Center in Nashville, summarizes 7 studies presented at the EHA 2025 Congress.

Guolo F, Minetto P, Clavio M, et al. Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia.

Measurable residual disease (MRD) negativity by flow cytometry was achieved in 77% of patients. With a median follow-up of 36 months, the median overall survival has not been reached at the time ...

Measurable residual disease (MRD) negativity by flow cytometry was achieved in 77% of patients. With a median follow-up of 36 months, the median overall survival has not been reached at the time ...

At the conference, Dr. Nicholas McCarthy, HCPC registered clinical scientist, Clinical Immunology Service for the University of Birmingham, UK, will lead a symposium focused on streamlining AML-MRD ...

"If we confirm MRD as a treatment-guiding biomarker, it can be used to guide the treatment of AML and CLL across Europe in the future," Michael Heuser, the lead research on the project and professor ...

Included among the presentations is the first data demonstrating the potential actionability of Mission Bio’s Tapestri® Single-Cell MRD (scMRD) AML Multiomics Assay, which will be presented ...

Session ID: 2025-05-27:b091fc4546a4dc3a3ba1beb Player Element ID: V3a8c5ff0_ec48_46b5_adc4_d844e269957b_6337624865112 ...

Measurable residual disease (MRD) can predict disease progression in patients who have acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML).

To achieve a consensus on a suitable panel and analysis strategy to report Acute Myeloid Leukemia - Measurable Residual Disease (AML-MRD) by flow cytometry, BD Life Sciences-Biosciences, a segment of ...